Microbiome: A Supportive or a Leading Actor in Lung Cancer?

Pathobiology - Tập 88 Số 2 - Trang 198-207 - 2021
Diana Martins1,2,3,4,5,6, Fernando Mendes1,4,5,6, Fernando Schmitt7,2,3
1Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal
2I3S–Instituto de Investigação e Inovação em Saúde, University of Porto, Porto, Portugal
3IPATIMUP – Institute of Molecular Pathology and Immunology of University of Porto, Porto, Portugal
4Polytechnic Institute of Coimbra, ESTESC-Coimbra Health School, Department of Biomedical Laboratory Sciences, Coimbra, Portugal
5University of Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), Coimbra, Portugal
6University of Coimbra, Coimbra Institute for Clinical and Biomedical Research (iCBR) area of Environment Genetics and Oncobiology (CIMAGO), Biophysics Institute of Faculty of Medicine, Coimbra, Portugal
7FMUP, Faculty of Medicine, University of Porto, Porto, Portugal

Tóm tắt

Lung cancer is still the leading cause of cancer death worldwide. Despite the major diagnostic and therapeutic innovations, the effect on mortality has been modest and the overall survival is still poor. Better understanding of the pathology of these tumors is necessary in order to develop personalized therapeutic strategies in lung cancer patients. Human microbiome has been associated with normal physiology and function, and increasing evidence points towards a key role of the microbiome in promoting the progression of lung disease. Studies have shown that although poorly understood, lung has a distinctive microbiome that may an important role in lung cancer development and progression, and interactions between microbial populations have the potential to influence disease, suggesting that microbiome can be an emerging target in cancer therapeutics. We will review mechanisms how the lung microbiota influences carcinogenesis, focusing on the bacterial dysbiosis and inflammation. Moreover, we will discuss the link between the microbiome and cancer and the consequences induced by the immune system, as the host microbiota plays an essential role in activating and modulating the immune response. We summarize current research advances in the lung microbiome and demonstrate the potential to exploit microbiome as a mechanism to prevent carcinogenesis and modulate therapeutic strategy, suggesting microbiome as a valuable approach in lung cancer patients.

Từ khóa


Tài liệu tham khảo

10.3322/caac.21492

10.1016/j.bbcan.2015.08.002

10.1016/j.clinthera.2016.03.026

10.1016/j.lungcan.2017.08.011

10.1016/j.lungcan.2016.10.016

10.21037/jtd.2018.12.88

10.1159/000487440

10.1007/s10549-019-05407-5

10.3332/ecancer.2018.866

10.1155/2019/1394191

10.1016/j.cell.2018.12.040

10.1186/s13059-020-01961-0

10.1371/journal.pone.0008578

10.1136/bmj.j5145

10.1371/journal.pone.0111228

10.1164/rccm.201104-0655OC

10.7861/clinmedicine.17-6-525

10.1038/nbt.3935

10.1016/S2213-2600(14)70028-1

10.1073/pnas.1107435109

10.1128/mBio.00129-10

10.1128/mBio.02287-16

10.1016/S0140-6736(14)61136-3

10.1146/annurev-physiol-021115-105238

10.1016/j.jcf.2014.03.004

10.1164/rccm.201111-2075OC

10.1016/j.tube.2015.05.017

10.5455/medarh.2017.71.212-214

10.1016/j.chom.2015.03.008

10.1016/j.jaci.2017.02.007

10.1164/rccm.201207-1160OE

10.1016/j.critrevonc.2019.06.004

10.1016/j.rmr.2010.05.020

10.1002/ijc.31098

10.1002/em.21878

10.1371/journal.pone.0178865

10.1038/onc.2017.28

10.1186/s13059-016-1021-1

10.1111/1348-0421.12157

10.1038/ni1213

10.1136/gutjnl-2015-309728

10.3748/wjg.v19.i40.6794

10.1038/ajg.2013.249

10.1038/nrgastro.2016.165

10.1007/s10620-012-2259-4

10.1177/1947601912465177

10.1378/chest.117.5_suppl_1.286S

10.1172/JCI31537

10.1371/journal.pone.0032106

10.3390/ijms20081915

10.1016/j.semcancer.2011.12.005

10.1038/nrm.2016.100

10.1016/j.canlet.2017.11.036

10.1038/nature06245

10.4049/jimmunol.165.7.3934

10.1016/j.molimm.2007.02.007

10.1002/ijc.24636

10.1038/nm.2015

10.1099/jmm.0.000371

10.1158/1940-6207.CAPR-10-0180

10.1038/nature12726

10.1073/pnas.1001261107

10.3389/fphys.2012.00448

10.3389/fmicb.2018.01757

10.1002/ijc.29111

10.1038/s41591-019-0377-7

10.1016/j.immuni.2016.06.001

10.1002/cncr.31907

10.1093/annonc/mdu106

10.1016/j.celrep.2018.08.090

10.4238/2015.May.25.16

10.1093/annonc/mdy103

10.21037/tlcr.2018.01.05

10.1056/NEJMoa1709937

10.3390/cancers11091269

10.15190/d.2018.4

10.1200/jco.2015.33.15_suppl.8032

10.1056/NEJMoa1810865

10.1007/s11060-016-2216-8

10.1111/1759-7714.12247

10.1200/JCO.2018.36.15_suppl.e15020

10.1200/JCO.18.01270

10.3389/fmicb.2019.00767

10.1007/s10552-015-0535-2

10.1371/journal.pone.0016384

10.1038/nri3769

10.1038/nrmicro.2017.14

10.4161/cc.26075

10.1126/science.1234415

10.1186/s12915-014-0087-z

10.1186/2049-2618-1-19

Thông tin
Thông tin xuất bản

Pathobiology

Tập 88 Số 2

198-207

Thông tin tác giả